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ABSTRACT
Objective To investigate clinical outcomes of coronary
intervention using a biolimus-eluting stent (BES)
compared with a sirolimus-eluting stent (SES) in patients
with acute myocardial infarction (AMI) in the Limus
Eluted from A Durable versus ERodable Stent (LEADERS)
coating trial at the final 5-year follow-up.
Methods The LEADERS trial is a multicentre all-comer
study, where patients (n=1707) were randomised to
percutaneous intervention with either BES containing
biodegradable polymer or SES containing durable
polymer. Out of 1707 patients enrolled in this trial, 573
patients had percutaneous coronary intervention for AMI
(BES=280, SES=293) and were included in the current
analysis. Patient-oriented composite endpoint (POCE,
including all death, all myocardial infarction (MI) and all
revascularisations), major adverse cardiac events (MACE,
including cardiac death, MI and clinically indicated target
vessel revascularisation) and stent thrombosis were
assessed at 5-year follow-up.
Results The baseline clinical, angiographic and
procedural characteristics were well matched between
BES and SES groups. In all patients with AMI, coronary
intervention with a BES, compared with SES, significantly
reduced POCE (28.9% vs 42.3%; relative risk (RR) 0.61,
95% CI 0.47 to 0.82, p=0.001) at 5-year follow-up.
There was also a reduction in MACE rate in the BES
group (18.2% vs 25.9%; RR 0.67, 95% CI 0.47 to
0.95, p=0.025); however, there was no difference in
cardiac death and stent thrombosis. In patients with
ST-elevation MI (STEMI), coronary intervention with BES
significantly reduced POCE (24.4% vs 39.3%; RR 0.55,
95% CI 0.36 to 0.85, p=0.006), MACE (12.6% vs
25.0%; RR 0.47, 95% CI 0.26 to 0.83, p=0.008) and
cardiac death (3.0% vs 11.4%; RR 0.25, 95% CI 0.08
to 0.75, p=0.007), along with a trend towards reduction
in definite stent thrombosis (3.7% vs 8.6%; RR 0.41,
95% CI 0.15 to 1.18, p=0.088), compared with SES.
Conclusions BES, compared with SES, significantly
improved safety and efficacy outcomes in patients with
AMI, especially those with STEMI, at 5-year follow-up.
Trial registration number NCT 00389220.
INTRODUCTION
Patients with acute myocardial infarction (AMI),
comprising ST-segment elevation myocardial
infarction (STEMI) and non-STEMI (NSTEMI), are
often treated with percutaneous coronary interven-
tion (PCI). Clinical trials have confirmed the efficacy
of PCI in the treatment of AMI.1–3 Furthermore,
use of stents has been shown to reduce major
adverse cardiac events (MACE) compared with
balloon angioplasty alone.4 However, the choice of
stent in patients undergoing PCI for AMI remains
debatable as AMI is a risk factor for device-related
adverse outcomes, including stent thrombosis.5
Bare metal stents (BMS) minimise the risk of acute
closure and constrictive remodelling compared with
balloon angioplasty, but are associated with restenosis
due to neointimal hyperplasia. First-generation
drug-eluting stents (DES) releasing sirolimus or pacli-
taxel from durable polymers reduce the need for
repeat revascularisation, but delay vessel healing due
to chronic inflammation induced by the presence of
durable polymer. Meta-analyses have shown no sig-
nificant difference in mortality, myocardial infarction
(MI) and stent thrombosis at 1 year between BMS
and first-generation DES, but have shown a signifi-
cant reduction in target vessel revascularisation in the
DES group.6 7 Conversely, clinical studies and
meta-analyses have also raised concerns about late
and very late stent thrombosis with use of DES in
AMI.8–11 Newer-generation DES with biocompatible
or biodegradable polymers have been shown to have
better safety and efficacy.12 13 In particular, DES with
biodegradable polymers provide controlled drug
release with subsequent degradation of the polymer
rendering the stent surface more close to a BMS after
the period of biodegradation. A few studies have
compared the newer-generation DES against first-
generation DES and reported conflicting outcomes at
1–3 years’ follow-up.14 15 Due to concerns about
very late stent thrombosis, further follow-up data are
warranted; however, to date, there are no longer-
term (5-year) follow-up data for comparison of the
newer-generation DES against first-generation DES in
patients with AMI. Thus, we hypothesised that cor-
onary intervention with a biodegradable polymer
biolimus-eluting stent (BES) would improve clinical
outcomes compared with intervention with a durable
polymer sirolimus-eluting stent (SES) in AMI subpo-
pulation of the ‘all-comers’ Limus Eluted from A
Durable versus ERodable Stent (LEADERS) coating
trial.
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Figure 1 Study flow chart. BES, biolimus-eluting stent; LEADERS, Limus Eluted from A Durable versus ERodable Stent coating; NSTEMI,
non-ST-segment elevation myocardial infarction; SES, sirolimus-eluting stent; STEMI, ST-segment elevation myocardial infarction.
Table 1 Baseline characteristics of acute myocardial infarction population stratified by stent type
Characteristics Biolimus-eluting stents (n=280) Sirolimus-eluting stents (n=293) p Value
Patient
Age, years 62.9±11.7 62.8±11.7 0.931
Men 215 (76.8%) 210 (71.7%) 0.162
BMI, kg/m2 27.5±4.4 27.8±4.6 0.427
Cardiovascular risk factors
Diabetes mellitus 55 (19.6%) 46 (15.7%) 0.216
Diabetes requiring insulin 17 (30.9%) 20 (43.5%) 0.192
Hypertension 181 (64.6%) 198 (67.6%) 0.458
Hypercholesterolaemia 152 (54.3%) 176 (60.1%) 0.162
Current smoker 107 (38.2%) 115 (39.2%) 0.799
Family history of CAD 98 (35%) 115 (39.2%) 0.293
History of MI 61 (21.8%) 61 (20.8%) 0.778
History of PCI 51 (18.2%) 51 (17.4%) 0.800
Previous CABG 13 (4.6%) 14 (4.8%) 0.939
Clinical presentation
Non-ST-elevation MI 145 (51.8%) 153 (52.2%) 0.918
ST-elevation MI (h) 135 (48.2%) 140 (47.8%) 0.918
<6 92 (68.1%) 83 (59.3%) 0.127
≥6–24 26 (19.3%) 36 (25.7%) 0.200
>24–72 12 (8.9%) 16 (11.4%) 0.486
>72 5 (3.7%) 5 (3.6%) 0.953
LVEF, % 51.5±10.1 51.4±11.8 0.734
Lesion complexity
Multivessel disease 69 (24.6%) 55 (18.8%) 0.088
Small-vessel disease (RVD <2.75 mm) 180 (64.3%) 183 (62.5%) 0.650
Long lesions (>20 mm) 94 (33.6%) 109 (37.2%) 0.364
Study lesions per patient 1.5±0.8 1.4±0.7 0.076
One 184 (65.7%) 213 (72.7%) 0.070
Two 72 (25.7%) 59 (20.1%) 0.112
Three 17 (6.1%) 17 (5.8%) 0.892
>Four 7 (2.5%) 4 (1.4%) 0.322
SYNTAX score (patient level) 14.7±8.8 15.3±8.7 0.321
BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; RVD, reference vessel
diameter.
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METHODS
The LEADERS trial was conducted in accordance with the prin-
ciples of the Declaration of Helsinki, and all site-specific
Institutional Review Boards and applicable regulatory agencies
approved the study protocol before study initiation.
LEADERS trial
Study design of the LEADERS trial (NCT 00389220) has been
previously described16 17 and is outlined in figure 1. Briefly, this
was an all-comers prospective, multicentre, randomised, assessor-
blind, non-inferiority trial. Patients (n=1707) with age
>18 years and symptomatic coronary artery disease with >50%
stenosis in one or more native coronary arteries or saphenous
vein bypass graft were included. Exclusion criteria were limited
and included pregnancy, known intolerance to aspirin, clopido-
grel, heparin, stainless steel, sirolimus, biolimus and contrast
material, inability to provide informed consent, patient participa-
tion in another trial before reaching the primary endpoint or
planned surgery within 6 months of PCI unless dual antiplatelet
therapy was maintained throughout the perioperative period.
Patients were 1:1 randomised to either BES (BioMatrix Flex,
Biosensors Europe, Morges, Switzerland) or SES (Cypher Select,
Cordis Corporation, Bridgewater, New Jersey, USA).
The current study included all patients with AMI (including
STEMI and NSTEMI) in the LEADERS cohort. As an ‘all-
comers’ trial, no limitation was placed on the number of treated
lesions, number of vessels or lesion length according to the ran-
domisation group. Patients were mandated to receive the same
stent type for all lesions. All procedures were performed accord-
ing to routine local clinical practice using standard techniques.
Study endpoints
The primary endpoint of the LEADERS trial was MACE,
defined as composite of cardiac death, MI (Q-wave and
non-Q-wave) or clinically indicated target vessel revascularisa-
tion within 9 months. For this substudy, we report MACE at 5
years and patient-oriented composite endpoint (POCE), a more
comprehensive endpoint including all-cause death, all MI and
any revascularisation that have been recommended by
Academic Research Consortium (ARC)18 after commencement
of the LEADERS trial. We have also included individual end-
points including cardiac mortality and stent thrombosis at
5-year follow-up. An independent clinical events committee
blindly adjudicated all events. Patient safety was assessed at pre-
specified intervals by an independent data and safety monitor-
ing board.
Table 2 Angiographic and procedural characteristics
Characteristics Biolimus-eluting stents (n=409) Sirolimus-eluting stents (n=399) p Value
Baseline QCA results
RVD, mm 2.69±0.62 2.65±0.58 0.529
MLD, mm 0.77±0.55 0.75±0.58 0.733
Diameter stenosis, % 70.9±19.9 70.9±21.9 0.967
Procedure
Number of stent per lesion 2.2±0.5 2.2±0.6 0.804
Total stent length per lesion 26.6±15 27.9±15.2 0.201
Direct stenting 129 (31.9%) 109 (27.4%) 0.185
Lesion success 401 (99.3%) 379 (97.9%) 0.112
TIMI flow (preprocedure) 0.891
0 98 (23.4%) 102 (25%)
1 7 (1.7%) 14 (3.4%)
2 18 (4.3%) 29 (7.1%)
3 283 (67.5%) 247 (60.5%)
TIMI flow (postprocedure) 0.966
0 2 (0.5%) 7 (1.8%)
1 0 (0%) 2 (0.5%)
2 6 (1.5%) 6 (1.5%)
3 400 (97.8%) 380 (95.7%)
Postprocedural QCA results
RVD, mm 2.78±0.49 2.77±0.48 0.640
MLD, mm 2.34±0.47 2.31±0.54 0.254
Diameter stenosis, % 15.6±9.0 16.4±13.9 0.348
Cardiac enzymes*
6–8 h postprocedure
Creatine kinase, U/L 946±1407 1081±1601 0.641
Creatine kinase MB, U/L 92±155 108±175 0.502
Troponin, ng/mL 5.7±13.9 7.9±23.1 0.447
18 h postprocedure or discharge
Creatine kinase, U/L 744±1301 687±956 0.676
Creatine kinase MB, U/L 57±81 61±86 0.755
Troponin, ng/mL 5.1±16.8 4.7±11.0 0.651
*Data on cardiac enzymes were available in 293 patients treated with sirolimus-eluting stent and 280 patients treated with biolimus-eluting stent.
MLD, minimum lumen diameter; QCA, quantitative coronary angiography; RVD, reference vessel diameter; TIMI; thrombolysis in myocardial infarction.
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Statistical analysis
Continuous variables are presented as mean±SD, and categor-
ical data as counts and percentages. Patients were analysed on
an intention-to-treat analysis. Time-to-event variables are pre-
sented as Kaplan–Meier curves, and incidences compared using
the log-rank test. All data were analysed using SAS V.9.3 (SAS
Institute, Cary, North Carolina, USA).
RESULTS
Patient characteristics
Out of 1707 patients enrolled in the LEADERS trial, 573
patients were with AMI—298 with NSTEMI and 275 with
STEMI. These patients were treated with either BES (n=280)
or SES (n=293). Study flow chart is shown in figure 1.
Patients in the BES and SES groups were well-matched for
baseline demographic, clinical and angiographic characteristics
(table 1).
Procedural and medication details
A lesion-level comparison for angiographic and procedural para-
meters did not show any difference between the two treatment
groups (table 2). There was also no difference in use of evidence-
based medication in the BES and SES groups, especially the use
of antiplatelet therapy throughout the 5-year follow-up (table 3).
Dual antiplatelet therapy was mandated for 12 months postde-
vice implantation; however, only two-third of patients in each
group were taking dual antiplatelet therapy at 1 year (BES 65.9%
vs SES 59.9%, p=0.154). At 5 years, majority of patients in both
groups were taking aspirin (93.6% vs 91%, p=0.280).
Clinical outcomes
All-cause mortality in the overall AMI population of LEADERS
trial was 4.7% at 1-year follow up and 13.3% at 5-year
follow-up (figure 2). Coronary intervention with a BES, com-
pared with SES, significantly reduced POCE (28.9% vs 42.3%,
relative risk (RR) 0.61, 95% CI 0.47 to 0.82, p=0.001) at
5-year follow-up (figure 2). Furthermore, MACE was also sig-
nificantly lower in the BES group (18.2% vs 25.9%, RR 0.67,
95% CI 0.47 to 0.95, p=0.025) at 5-year follow-up (figure 3).
However, there was no difference in individual endpoints of
death, cardiac death, MI, target vessel revascularisation, target
lesion revascularisation or stent thrombosis in the BES and SES
groups (figure 2). There was a trend towards reduction in the
risk of definite (4.3% vs 6.8%, RR 0.61, 95% CI 0.30 to 1.25,
p=0.174) and definite/probable (5.4% vs 8.5%, HR 0.61, 95%
CI 0.32 to 1.16, p=0.128) stent thrombosis with BES compared
with SES (figure 2). The incidence of stent thrombosis according
to ARC-defined time periods of acute, subacute, late and very
late is shown in table 4. This benefit of BES on stent thrombosis
was seen at both short-term and long-term follow-up as evident
by the landmark analysis (figure 4).
Stratified analysis according to AMI type
Dividing AMI population further into STEMI and NSTEMI
groups also revealed similar baseline characteristics among the
two treatment arms (see online supplementary table S1).
Angiographic and procedural characteristics of STEMI and
NSTEMI subgroups are shown in online supplementary table
S2. Five-year outcomes stratified by STEMI and NSTEMI popu-
lation revealed that coronary intervention with BES improved
POCE compared with intervention with SES in both AMI
groups (see online supplementary table S3). In the STEMI
group, cardiac death and MACE were significantly lower in the
BES group compared with SES group; however, there was no
difference in the NSTEMI group (figure 3). Furthermore, there
was a trend towards reduction in definite (3.7% vs 8.6%, RR
0.41, 95% CI 0.15 to 1.18, p=0.088) and definite/probable
(4.4% vs 10.0%, RR 0.43, 95% CI 0.16 to 1.11, p=0.070)
stent thrombosis with use of BES in STEMI population (see
online supplementary table S3).
DISCUSSION
This post hoc analysis of patients with AMI in the LEADERS
trial has shown improved 5-year clinical outcomes with coron-
ary intervention using BES containing biodegradable polymer
reducing POCE and MACE. Coronary intervention with a BES,
compared with SES, was particularly beneficial in STEMI popu-
lation, reducing POCE, MACE, cardiac death, repeat revascular-
isation and stent thrombosis.
The choice of stent in patients undergoing PCI for AMI has
remained debatable. Coronary intervention with first-generation
DES-eluting sirolimus or paclitaxel from a durable polymer has
generally reduced need for revascularisation, but has shown no
improvement in mortality compared with intervention with
BMS.6 19 20 Furthermore, risk of late stent thrombosis with first-
generation DES tends to offset benefit from reduction in revas-
cularisation in patients with STEMI as seen in real-world regis-
tries,8 9 clinical trials21 and a recent meta-analysis of 15 clinical
trials comparing BMS and first-generation DES.10
Newer-generation DES, eluting zotarolimus, everolimus or bio-
limus from biocompatible or biodegradable polymers, have been











127 (45.4%) 118 (40.3%) 0.219
Loading dose clopidogrel 235 (83.9%) 245 (83.6%) 0.920
300 mg 35 (12.5%) 42 (14.3%) 0.520
600 mg 185 (66.1%) 188 (64.2%) 0.632
Other 15 (5.3%) 15 (5.1%) 0.791
At 1 month
Aspirin 262 (98.1%) 270 (98.9%) 0.4568
Clopidogrel 266 (99.6%) 266 (97.4%) 0.0352
DAPT 262 (98.1%) 263 (96.3%) 0.2056
Statins 254 (90.71%) 259 (88.4%) 0.3649
β-blockers 243 (86.79%) 248 (84.64%) 0.4638
ACE inhibitors 199 (71.07%) 216 (73.72%) 0.4782
At 1 year
Aspirin 254 (97.3%) 260 (95.6%) 0.2816
Clopidogrel 178 (68.2%) 169 (62.1%) 0.1418
DAPT 172 (65.9%) 163 (59.9%) 0.1536
Statins 243 (86.79%) 245 (83.62%) 0.2862
β-blockers 228 (81.43%) 241 (82.25%) 0.7981
ACE inhibitors 175 (62.5%) 190 (64.85%) 0.5593
At 5 years
Aspirin 212 (91%) 221 (93.6%) 0.2798
Clopidogrel 24 (10.3%) 25 (10.6%) 0.9174
DAPT 17 (7.3%) 22 (9.3%) 0.4269
Statins 204 (72.86%) 200 (68.26%) 0.2277
β-blockers 195 (69.64%) 193 (65.87%) 0.3343
ACE inhibitors 141 (50.36%) 142 (48.46%) 0.6505
DAPT, dual antiplatelet therapy.
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shown to offer better safety outcomes. The EXAMINATION
(clinical Evaluation of the Xience-V stent in Acute Myocardial
INfArcTION) trial compared the durable polymer
everolimus-eluting stent with BMS in patients with STEMI and
showed reduction in target lesion revascularisation (3.7% vs 6.8%,
p=0.008) but no difference in the composite endpoint of all-cause
Figure 2 Clinical outcomes in patients with acute myocardial infarction at 5-year follow-up. *Patient-oriented composite endpoint (all-cause
death, MI, all-cause revascularisation). †Composite of cardiac death, MI and clinically indicated target vessel revascularisation. BES, biolimus-eluting
stent; MACE, major adverse cardiac event; MI, myocardial infarction; POCE, patient-oriented composite endpoint; RR, relative risk; SES,
sirolimus-eluting stent; TLR, target lesion revascularisation; TVR, target vessel revascularisation.
Figure 3 Kaplan–Meier curves for 5-year cardiac death and MACE. MACE and cardiac death were significantly lower in BES group in patients with
STEMI (A, C). No differences were detected statistically on MACE and cardiac death between the 2 groups in patients with NSTEMI (B, D).
BES, biolimus-eluting stent; MACE, major adverse cardiac event; NSTEMI, non-ST-segment elevation myocardial infarction; SES, sirolimus-eluting
stent; STEMI, ST-elevation myocardial infarction.
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death, MI and target lesion revascularisation (11.9% vs 14.2%,
p=0.19) at 1-year follow-up.12 The COMFORTABLE-AMI
(Comparison of Biolimus Eluted From an Erodible Stent Coating
With Bare Metal Stents in Acute ST-Elevation Myocardial
Infarction) trial, comparing BES against BMS, demonstrated the
superiority of the biodegradable polymer BES to BMS with the
identical metallic platform in terms of a significant reduction in
the primary endpoint of MACE defined as the composite of
cardiac death, target vessel-related MI and ischaemia-driven target
lesion revascularisation (4.3% vs 8.7%, p=0.004) and POCE
(8.4% vs 12.2%, p=0.04) at 1-year follow-up.13 Definite stent
thrombosis was numerically lower in the BES group (0.9% vs
2.1%, p=0.10), and there was no difference in mortality (2.9% vs
3.5%, p=0.53).13 Two-year follow-up results were recently
reported, showing persistent benefit of BES over BMS.22 A pooled
analysis of the EXAMINATION and COMFORTABLE-AMI trials
also showed that newer-generation DES improve safety and effi-
cacy compared with BMS at 1-year follow-up.23 Further follow-up
is awaited to evaluate the long-term impact of durable polymer
newer-generation DES on very late stent thrombosis and its asso-
ciated clinical impact.
Previous studies comparing zotarolimus-eluting and everoli-
mus-eluting second-generation stents have not been able to show
a convincing superiority over the first-generation DES in patients
with AMI. ZEST-AMI compared the efficacy and safety of
zotarolimus-eluting stents (n=108) against first-generation SES
(n=110) and paclitaxel-eluting stents (n=110) in patients with
STEMI. At 12 months, cumulative incidence rates of primary
endpoint (MACE, composite of death, MI and ischaemia-driven
target vessel revascularisation) in the zotarolimus-eluting, siroli-
mus-eluting and paclitaxel-eluting stents were 11.3%, 8.2% and
8.2%, respectively (p=0.834).15 XAMI (XienceV Stent vs.
Cypher Stent in Primary PCI for Acute Myocardial Infarction)
trial has compared everolimus-eluting stent against the first-
generation SES and reported a lower rate of MACE (composite
of cardiac death, AMI or any target vessel revascularisation) with
everolimus-eluting stent (4.0% vs 7.7%, p=0.048) but no signifi-
cant difference in cardiac mortality (1.5% vs 2.7%, p=0.36) or
the incidence of definite/probable stent thrombosis (1.2% vs
2.7%, p=0.21) at 1 year.14 However, at 3-year follow-up, there
was no difference in everolimus-eluting stent and SES groups for
MACE (everolimus-eluting stent 8.0% vs SES 10.5%, p=0.30),
cardiac death (2.5% vs 2.7%, p=0.86) and definite/probable
stent thrombosis (2.3% vs 3.2%, p=0.60). AMI substudies of
other trials comparing everolimus-eluting stent against SES,
including Basket-PROVE (the BASKET-Prospective Validation
Examination),24 EXCELLENT (Efficacy of Xience/Promus
Versus Cypher to Reduce Late Loss After Stenting)25 and
SORT-OUT IV (The Scandinavian Organization for Randomized
Trials with Clinical Outcome IV),26 have also showed no signifi-
cant advantage of everolimus-eluting stent over SES in patients
with AMI or STEMI. Our study, for the first time, has shown that
BES with biodegradable polymer, compared with the durable
polymer SES, reduced cardiac death as well as stent thrombosis
in STEMI population at 5-year follow-up.
The main strengths of the current study, compared with previ-
ous reports of newer-generation DES in AMI population,
include having an ‘all-comers’ AMI population and the longest
available (5-year) follow-up. Due to an ‘all-comer’ design, this
study included patients with STEMI with complex anatomical
disease (22% patients had multivessel disease, 38% patients had
lesions >20 mm). This may explain a slightly higher incidence
of adverse events in both arms of study compared with other
reports. The sample size in this study is moderate; however, due
to longer follow-up, we were able to demonstrate a beneficial
effect of BES in reducing cardiac death, which was not evident
at 1-year follow-up of the current study as well as in the
COMFORTABLE-AMI trial. The long-term follow-up also pro-
vides additional insights into late stent thrombosis, which is
largely blamed on durable polymer.27 Undoubtedly, stent throm-
bosis is multifactorial in origin; patient-related, procedure-
related or device-related factors may play a role.27 Our results
indicate that patients with AMI remain at a significant risk of
late stent thrombosis even in the BES group (incidence of late
stent thrombosis in the BES group: non-AMI 0.3%, STEMI
1.6%, NSTEMI 3.0%).28 Therefore, adhering to an evidence-
based medical therapy, including antiplatelet drugs, is vital in
these high-risk patients. Furthermore, the dual antiplatelet
regimen in the LEADERS trial included aspirin and clopidogrel.
Table 4 Stent thrombosis for patients with acute myocardial









Definite ST 6 (2.1%) 11 (3.8%) 0.254
Definite or probable ST 7 (2.5%) 13 (4.4%) 0.206
Late (31–360 days)
Definite ST 2 (0.7%) 2 (0.7%) 0.990
Definite or probable ST 2 (0.7%) 2 (0.7%) 0.990
Very late (361–1800 days)
Definite ST 4 (1.6%) 7 (2.7%) 0.364
Definite or probable ST 6 (2.3%) 10 (3.8%) 0.318
ST, stent thrombosis.
Figure 4 Kaplan–Meier curves for stent thrombosis with landmark analysis. AMI, acute myocardial infarction; BES, biolimus-eluting stent; SES,
sirolimus-eluting stent.
276 Zhang Y-J, et al. Heart 2015;101:271–278. doi:10.1136/heartjnl-2014-306359
Coronary artery disease
group.bmj.com on April 28, 2017 - Published by http://heart.bmj.com/Downloaded from 
However, newer P2Y12 inhibitors (prasugrel and ticagrelor)
with better clinical outcomes have largely replaced clopidogrel
as part of dual antiplatelet therapy.29 30
This study has several limitations. It is a post hoc analysis of
the data, and results should be viewed with caution. Some base-
line characteristics, including ischaemia time, door-to-balloon
time and thrombectomy use, were unavailable in both of the
studied groups. The trial was not powered for stent thrombosis
in various subgroups; therefore, possibility of a type I statistical
error cannot be excluded. Type I error was also not corrected
for multiple comparison. However, stent thrombosis according
to the definitions of ARC was a prespecified endpoint and was
adjudicated by an independent clinical events committee, and
the incidence of definite stent thrombosis continued to diverge
between the two investigated devices up to 5 years, which
would make the play of chance unlikely.
CONCLUSIONS
The newer-generation BES with biodegradable polymer compared
with SES with durable polymer provided significant improvements
in clinical outcomes in patients with AMI at 5-year follow-up. The
benefit appeared more significant in the subgroup of patients with
STEMI. Our results suggest that BES should be favourably consid-
ered for treating patients with STEMI. However, long-term
follow-up of the COMFORTABLE-AMI trial and further larger
studies are needed to confirm our findings.
Key messages
What is already known on this subject?
Clinical trials have confirmed the efficacy of percutaneous
coronary intervention (PCI) in the treatment of acute myocardial
infarction. Use of stents has been shown to reduce major
adverse cardiac events compared with balloon angioplasty
alone. However, the choice of stent in patients undergoing PCI
for acute myocardial infarction remains debatable.
What might this study add?
This study highlights that patients with acute myocardial
infarction have shown improved 5-year clinical outcomes with
biolimus-eluting stent (BES) containing biodegradable polymer
reducing major cardiac adverse events (absolute risk reduction:
7.7%). Coronary intervention with a BES, compared with a
sirolimus-eluting stent (SES), was particularly beneficial in
ST-elevation myocardial infarction (STEMI) population.
How might this impact on clinical practice?
This study, for the first time, has shown that coronary
intervention with a biodegradable polymer BES, compared with
the durable polymer SES, reduced cardiac death as well as stent
thrombosis in STEMI population at 5-year follow-up; hence, use
of the newer generation biodegradable polymer BES should be
recommended in patients with STEMI.
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